Contraindications to receiving the Prevnar 13 (PCV13) vaccine documented in Wyeth Pharmaceuticals package insert include persons who have experienced a severe allergic reaction or anaphylaxis to any component of Prevnar 13 (PCV13) or any vaccine containing diphtheria toxoid.
The Prevnar 13 (PCV13) package insert warns that apnea following administration with Prevnar 13 (PCV13) has occurred in infants born prematurely. The infant’s medical status as well as the possible risks and potential benefits to vaccination should be carefully evaluated prior to considering Prevnar 13 (PCV13).
Persons with altered immune systems may have a reduced response to vaccination with Prevnar 13 (PCV13). Data on the administration of Prevnar 13 (PCV13) to women who are pregnant is insufficient for Wyeth pharmaceuticals to provide any information on the risks of vaccination during pregnancy.
There is no available data on the effects of Prevnar 13 (PCV13) on the breast-fed infant and it is recommended that breastfeeding women carefully consider the possible risk of vaccination on the infant when considering this vaccine.
Prevnar 13 (PCV13) has not been studied for its potential to cause cancer, genetic mutations or male infertility. Studies on female fertility were limited to the vaccine’s effects on female rabbits.
